Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nectar Lifesciences Ltd. ( (IN:NECLIFE) ) has shared an announcement.
Nectar Lifesciences Ltd. recently underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare and the Spanish Agency of Medicines and Medical Devices at its API manufacturing facility in Punjab, India. The inspection resulted in seven observations, including four critical ones, prompting the company to prepare a Corrective Action and Preventive Action report to address these issues. The company emphasizes its commitment to quality and compliance, with a re-inspection by the European regulator anticipated, which could lead to EuGMP approval.
More about Nectar Lifesciences Ltd.
Nectar Lifesciences Ltd. operates in the pharmaceutical industry, focusing on the manufacturing of active pharmaceutical ingredients (APIs). The company is committed to maintaining high-quality standards and compliance with global regulatory requirements.
YTD Price Performance: -26.55%
Average Trading Volume: 461,070
Current Market Cap: 6.55B INR
See more insights into NECLIFE stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue